See more : The Music Acquisition Corporation (TMAC) Income Statement Analysis – Financial Results
Complete financial analysis of Q32 Bio Inc. (QTTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Q32 Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Suzuken Co., Ltd. (9987.T) Income Statement Analysis – Financial Results
- USS Co., Ltd. (USSJF) Income Statement Analysis – Financial Results
- Capstone Therapeutics Corp. (CAPS) Income Statement Analysis – Financial Results
- Cariloha, Inc. (ALOHA) Income Statement Analysis – Financial Results
- Maxvision Technology Corp. (002990.SZ) Income Statement Analysis – Financial Results
Q32 Bio Inc. (QTTB)
Industry: Biotechnology
Sector: Healthcare
About Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16M | 6.65M | 33.97M | 2.70M | 1.67M | 5.32M | 0.00 | 0.00 |
| Cost of Revenue | 578.00K | 2.60M | 9.54M | 0.00 | 0.00 | 0.00 | 684.21K | 239.80K |
| Gross Profit | 578.00K | 4.05M | 24.43M | 2.70M | 1.67M | 5.32M | -684.21K | -239.80K |
| Gross Profit Ratio | 50.00% | 60.92% | 71.91% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 62.00M | 35.81M | 29.93M | 100.39M | 89.40M | 47.95M | 21.38M | 5.69M |
| General & Administrative | 0.00 | 10.06M | 6.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.68M | 10.06M | 6.76M | 23.67M | 15.89M | 16.01M | 7.60M | 4.07M |
| Other Expenses | 0.00 | -1.12M | -324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 92.68M | 45.88M | 36.69M | 124.06M | 105.29M | 63.96M | 28.97M | 9.76M |
| Cost & Expenses | 93.26M | 45.88M | 36.69M | 132.97M | 111.61M | 65.25M | 29.66M | 10.00M |
| Interest Income | 5.58M | 0.00 | 0.00 | 1.57M | 6.03M | 4.35M | 542.64K | 24.20K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 578.00K | 2.60M | 9.54M | 8.90M | 6.32M | 1.29M | 684.21K | 239.80K |
| EBITDA | -86.50M | -38.86M | -86.22M | -121.36M | -103.63M | -58.64M | -29.31M | -7.81M |
| EBITDA Ratio | -7,482.87% | -548.08% | -107.87% | -4,491.45% | -6,219.99% | -1,101.79% | 0.00% | 0.00% |
| Operating Income | -92.10M | -39.23M | -36.69M | -130.26M | -109.94M | -59.93M | -29.66M | -10.00M |
| Operating Income Ratio | -7,967.30% | -589.76% | -108.01% | -4,820.98% | -6,599.22% | -1,126.01% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.02M | -3.52M | -324.00K | 1.57M | 6.03M | 4.35M | -333.37K | 1.95M |
| Income Before Tax | -87.08M | -42.75M | -37.02M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Income Before Tax Ratio | -7,532.87% | -642.72% | -108.97% | -4,762.92% | -6,237.45% | -1,044.29% | 0.00% | 0.00% |
| Income Tax Expense | 25.88M | 62.00K | 547.00K | -1.00 | 0.00 | 0.00 | -4.00 | 2.00 |
| Net Income | -112.96M | -42.81M | -37.56M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Net Income Ratio | -9,771.71% | -643.65% | -110.58% | -4,762.92% | -6,237.45% | -1,044.29% | 0.00% | 0.00% |
| EPS | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| EPS Diluted | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| Weighted Avg Shares Out | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
| Weighted Avg Shares Out (Dil) | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Source: https://incomestatements.info
Category: Stock Reports